Blockchain Registration Transaction Record

ABVC's Oncology Licensing Deal with OncoX Highlights Scalable Royalty Strategy

ABVC BioPharma's affiliate OncoX acquires Lycogen® platform in a $4.06M deal, promising significant revenue through innovative oncology and nutraceutical solutions.

This news is significant as it showcases ABVC BioPharma's innovative approach to generating non-dilutive revenue through strategic licensing and affiliate partnerships. The acquisition of the Lycogen® platform by OncoX not only expands ABVC's oncology portfolio but also positions the company to capitalize on the growing global demand for natural compound-based therapies. With the oncology drug market expected to reach $484 billion by 2032, this deal could have far-reaching implications for the treatment of cancer and metabolic diseases, offering new hope for patients and creating value for shareholders.